The FDA approved Dawnzera for the prophylaxis of Hereditary Angioedema (HAE), an RNA-targeted therapy developed by Ionis Pharmaceuticals. It is being compared to treatments from BioCryst and Takeda.
1 report, 1 independent
Updated Aug 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved Dawnzera for the prophylaxis of Hereditary Angioedema (HAE), an RNA-targeted therapy developed by Ionis Pharmaceuticals. It is being compared to treatments from BioCryst and Takeda.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Coverage
Newest first; wire copies grouped- BenzingaIonis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:ION